DDInter8 DDInter1676
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resistant prostate cancer and hormone-sensitive high-risk metastatic prostate cancer.[L40968, L40193, L47740, L47745] As abiraterone has poor oral bioavailability and is susceptible to hydrolysis by esterases, abiraterone acetate was developed as an orally bioavailable prodrug with enhanced stability and absorption.[A3811, A260835]
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Abiraterone {u} (Compound) resembles {v} (Compound) Testosterone
Abiraterone {u} (Compound) treats {v} (Disease) prostate cancer
Abiraterone {u} (Compound) binds {v} (Gene) ABCC1
Abiraterone {u} (Compound) causes {v} (Side Effect) Hypokalaemia
Abiraterone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Abiraterone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Abiraterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Torasemide
Abiraterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lithium carbonate
Abiraterone {u} may lead to a major life threatening interaction when taken with {v} Dofetilide
Abiraterone {u} may lead to a major life threatening interaction when taken with {v} Ivabradine
Abiraterone (Compound) resembles Testosterone (Compound)
Abiraterone (Compound) treats prostate cancer (Disease)
Abiraterone (Compound) binds ABCC1 (Gene)
Abiraterone (Compound) causes Hypokalaemia (Side Effect)
Abiraterone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Abiraterone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Torasemide
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Abiraterone may lead to a major life threatening interaction when taken with Dofetilide
Abiraterone may lead to a major life threatening interaction when taken with Ivabradine